CA
NZ
UK
AU
IND
US
…
Awakn Life Sciences Corp., a biotechnology company, engages in the research, development, operation, and delivery of psychedelic therapeutics to treat addiction and other mental health conditions in North America and Europe. It develops AWKN-001, a novel medication-assisted treatments (MAT) consisting of racemic ketamine, delivered intravenously, and manualized relapse prevention cognitive behavioural therapy (CBT) which is in phase 3 trials to treat severe Alcohol Use Disorder (AUD); AWKN-002, a novel MAT consisting of a patent pending proprietary S"ketamine oral thin film, and manualized relapse prevention CBT to treat AUD; and MDMA/Zydis, an investigational medicinal product entactogen that acts as a releaser and reuptake inhibitor of serotonin, norepinephrine, and dopamine. The company has a collaboration agreement with the University of Exeter for exploring the use of ketamine-assisted therapy to treat Severe AUD; with Graft Polymer (UK) PLC to develop chemical entity series programme for trauma-related mental health disorders; and with the University of Nottingham focusing on evaluating the company's lead aminoindane series and its potential to enhance social cognition and pro-social behaviors. Awakn Life Sciences Corp. is headquartered in Toronto, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2023-01-31 | 2022-01-31 | 2021-01-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2023-01-31 | 2022-01-31 | 2021-01-31 |
| Income before tax | -9.65M | -16.47M | - |
| Minority interest | 0.51M | 0.53M | 0.14M |
| Net income | -9.14M | -15.95M | - |
| Selling general administrative | 5.46M | 6.54M | - |
| Gross profit | -1.55M | -0.28M | - |
| Reconciled depreciation | 0.60M | 0.18M | - |
| Ebit | - | -9.79M | -0.84M |
| Ebitda | -8.78M | -16.08M | - |
| Operating income | -9.19M | -9.79M | - |
| Interest expense | 0.27M | 0.21M | 0.00M |
| Tax provision | 0.00M | 0.00M | - |
| Net interest income | -0.27M | -0.21M | - |
| Total revenue | 1.50M | 0.24M | - |
| Total operating expenses | 10.69M | 10.03M | - |
| Cost of revenue | 3.05M | 0.51M | - |
| Total other income expense net | -0.19M | -6.47M | - |
| Net income from continuing ops | -9.65M | -16.47M | - |
| Net income applicable to common shares | - | -15.95M | -1.26M |
| Breakdown | 2024-01-31 | 2023-01-31 | 2022-01-31 | 2021-01-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2024-01-31 | 2023-01-31 | 2022-01-31 | 2021-01-31 |
| Total assets | 0.54M | 4.39M | 6.88M | - |
| Intangible assets | 0.05M | 0.06M | 0.05M | - |
| Total liab | 2.07M | 4.44M | 3.85M | - |
| Total stockholder equity | -1.53M | 0.85M | 3.41M | - |
| Other current liab | - | 0.06M | 0.28M | 0.03M |
| Common stock | - | - | 16.14M | 1.20M |
| Capital stock | 22.22M | 20.01M | 16.14M | - |
| Retained earnings | -30.97M | -25.95M | -16.81M | -0.87M |
| Other liab | - | - | 0.54M | - |
| Good will | - | 0.00M | 0.93M | - |
| Other assets | - | - | 0.17M | - |
| Cash | 0.41M | 0.55M | 1.62M | - |
| Total current liabilities | 2.07M | 2.46M | 1.86M | 0.24M |
| Net debt | - | 0.13M | - | - |
| Other stockholder equity | - | - | 4.08M | -0.00M |
| Property plant equipment | - | - | 3.61M | 0.35M |
| Total current assets | 0.50M | 0.98M | 2.11M | 0.48M |
| Net tangible assets | - | - | 2.43M | 0.33M |
| Net receivables | 0.01M | 0.04M | 0.13M | 0.02M |
| Long term debt | - | 0.68M | - | - |
| Accounts payable | - | - | 1.22M | 0.20M |
| Non current assets total | 0.05M | 3.42M | 4.76M | - |
| Capital lease obligations | 0.00M | 1.62M | 1.81M | - |
| Breakdown | 2023-01-31 | 2022-01-31 | 2021-01-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2023-01-31 | 2022-01-31 | 2021-01-31 |
| Investments | -0.10M | -1.69M | - |
| Change to liabilities | - | 1.03M | 0.30M |
| Total cashflows from investing activities | - | -1.69M | -0.29M |
| Net borrowings | - | 3.68M | -0.05M |
| Total cash from financing activities | 6.40M | 11.50M | 1.41M |
| Change to operating activities | - | -0.49M | -0.13M |
| Net income | -9.14M | -15.95M | -1.26M |
| Change in cash | -1.06M | 1.26M | 0.49M |
| Begin period cash flow | 1.62M | 0.37M | - |
| End period cash flow | 0.55M | 1.62M | 0.37M |
| Total cash from operating activities | -7.36M | -8.59M | -0.63M |
| Issuance of capital stock | 5.97M | 7.49M | - |
| Depreciation | 0.60M | 0.18M | 0.02M |
| Change to account receivables | -0.02M | -0.00M | -0.00M |
| Other cashflows from financing activities | - | 0.33M | 0.33M |
| Change to netincome | - | 6.64M | 0.44M |
| Capital expenditures | 0.10M | 1.70M | 0.27M |
| Change in working capital | 0.51M | 0.54M | - |
| Stock based compensation | 0.63M | 1.09M | - |
| Other non cash items | -0.35M | 0.99M | - |
| Free cash flow | -7.46M | -10.29M | - |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk A/S |
0.45 1.12% |
40.45 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-5.73 1.03% |
553.15 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
33.37 3.60% |
961.26 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Awakn Life Sciences Corp., a biotechnology company, engages in the research, development, operation, and delivery of psychedelic therapeutics to treat addiction and other mental health conditions in North America and Europe. It develops AWKN-001, a novel medication-assisted treatments (MAT) consisting of racemic ketamine, delivered intravenously, and manualized relapse prevention cognitive behavioural therapy (CBT) which is in phase 3 trials to treat severe Alcohol Use Disorder (AUD); AWKN-002, a novel MAT consisting of a patent pending proprietary S"ketamine oral thin film, and manualized relapse prevention CBT to treat AUD; and MDMA/Zydis, an investigational medicinal product entactogen that acts as a releaser and reuptake inhibitor of serotonin, norepinephrine, and dopamine. The company has a collaboration agreement with the University of Exeter for exploring the use of ketamine-assisted therapy to treat Severe AUD; with Graft Polymer (UK) PLC to develop chemical entity series programme for trauma-related mental health disorders; and with the University of Nottingham focusing on evaluating the company's lead aminoindane series and its potential to enhance social cognition and pro-social behaviors. Awakn Life Sciences Corp. is headquartered in Toronto, Canada.
| Name | Title | Year Born |
|---|---|---|
| Mr. Anthony Tennyson | Co-founder, Pres, CEO & Director | NA |
| Dr. Benjamin Sessa B.Sc., MBBS | Co-Founder, Head of Psychedelic Medicine & Member of Clinical Advisory Board | NA |
| Mr. James Collins | Chief Operating Officer | NA |
| Dr. Shaun McNulty Ph.D. | Chief Scientific Officer & Member of Pre-Clinical Advisory Board | NA |
| Mr. George Scorsis | Co-founder & Chairman | 1976 |
| Mr. Jonathan James Held C.A., CPA, CA | Co-Founder & CFO | 1986 |
| Mr. Gordo Whittaker | Chief Marketing Officer | NA |
| Prof. David John Nutt DM, FMedSci, FRCP, FRCPsych, FSB, Ph.D. | Chair of Pre-Clinical & Clinical Advisory Board and Chief Research Officer | NA |
| Prof. Celia Morgan | Head of Ketamine-Assisted Therapy & Member of Clinical Advisory Board | NA |
| Dr. Lowan H. Stewart F.A.C.E.P., M.D. | Regional Director of Nordics & MD of Awakn Oslo AS | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.09%
Communication Services
+0.21%
Consumer Cyclical
+1.14%
Consumer Defensive
+0.88%
Energy
-2.61%
Financial Services
+0.70%
Financials
+0.41%
Healthcare
-0.75%
Industrials
+0.35%
Real Estate
+0.57%
Technology
-1.17%
Utilities
+0.05%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...